+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Small Molecules Drugs for Inflammatory Bowel Diseases Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Small Molecules Drugs for Inflammatory Bowel Diseases Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Small Molecules Drugs for Inflammatory Bowel Diseases Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 195 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6083023
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Inflammatory bowel diseases (IBDs) such as Crohn’s disease and ulcerative colitis represent a significant and growing global healthcare challenge. These chronic, relapsing conditions lead to debilitating symptoms, diminished quality of life, and substantial economic burden. In recent years, the therapeutic landscape for IBD has expanded beyond biologics and corticosteroids to include an increasingly diverse array of small molecule drugs that offer targeted mechanisms of action, improved administration routes, and favorable safety profiles.

This executive summary provides a concise yet comprehensive overview of the small molecule drug segment within the IBD market. It highlights the pivotal shifts that are transforming treatment paradigms, analyzes the potential impact of the United States tariffs implemented in 2025, and distills the market’s key segmentation, regional dynamics, and competitive landscape. By articulating actionable insights and strategic recommendations, this summary aims to inform decision-makers, clinicians, and industry stakeholders about the critical factors shaping innovation and investment in IBD therapeutics.

Transformative Shifts Reshaping the IBD Treatment Landscape

The IBD treatment landscape is undergoing a period of profound transformation driven by scientific advances, regulatory evolution, and patient-centric care models. First, the emergence of next-generation Janus kinase inhibitors has introduced oral therapies that target intracellular signaling pathways with unprecedented selectivity, offering alternatives to parenteral biologics. Moreover, the refinement of integrin antagonists and interleukin inhibitors has broadened therapeutic options for patients who exhibit refractory or secondary loss of response to tumor necrosis factor inhibitors.

Furthermore, the integration of real-world evidence and advanced biomarkers is enabling precision medicine approaches that tailor treatment regimens based on genetic, immunologic, and microbiome profiles. Digital health solutions such as remote monitoring applications and telemedicine platforms are fostering continuous disease management outside of traditional clinical settings. In addition, emerging regulatory frameworks that incentivize accelerated approval pathways and post-market evidence generation are expediting patient access to innovative small molecule therapies. Consequently, the interplay of these scientific, technological, and policy shifts is empowering clinicians to implement more individualized, effective, and sustainable care strategies for IBD.

Assessing the Cumulative Impact of United States Tariffs in 2025

In 2025, the United States introduced revised tariff measures on active pharmaceutical ingredients (APIs) and finished small molecule products, aimed at supporting domestic manufacturing and protecting intellectual property. While these tariffs are designed to strengthen the U.S. supply chain resilience, they also introduce incremental cost pressures that reverberate across the value chain. Raw material suppliers have reported increased production expenses, which in turn affect formulation manufacturers and contract development and manufacturing organizations.

Consequently, pharmaceutical companies are exploring strategies to mitigate tariff-related cost escalation, including nearshoring API synthesis, renegotiating supplier contracts, and optimizing batch yields through process intensification. Some market players have also initiated dialogues with regulatory bodies to secure duty exemptions for select orphan or critical IBD therapies. Meanwhile, healthcare providers face reimbursement challenges as payers adjust formularies to balance patient access with budgetary constraints. These dynamics underscore the need for agile pricing strategies and robust supply chain governance to sustain the affordability and availability of small molecule treatments in IBD.

Key Segmentation Insights Across Multiple Analytical Dimensions

The market for small molecule IBD therapies can be dissected through multiple analytical lenses designed to capture distinct dimensions of disease management, pharmacology, delivery formats, patient populations, and care settings. Disease Type segmentation differentiates Crohn’s disease into active and remission maintenance phases while separating ulcerative colitis into mild-to-moderate and moderate-to-severe categories, highlighting varying treatment intensities and clinical outcomes. Drug Class segmentation spans 5-aminosalicylates with oral and rectal administrations, biologics encompassing integrin antagonists, interleukin inhibitors, and TNF inhibitors, immune modifiers divided into immunomodulators and immunosuppressants, and Janus kinase inhibitors classified as oral JAK and selective JAK agents, illustrating the rich pharmacotherapeutic tapestry. Dosage Form segmentation covers capsules, injections-further characterized by pre-filled syringes and vials-suppositories, and tablets, reflecting patient preference and adherence considerations. Distribution Channel segmentation encompasses hospital, online, and retail pharmacies to reveal channel-specific procurement and dispensing trends. Patient Demographics segmentation distinguishes adult populations-spanning young, middle-aged, and senior adults-from pediatric cohorts, underscoring age-related therapeutic needs. End-User segmentation examines clinical delivery across clinics, homecare settings, and hospitals to inform site-of-care strategies. Drug Origin segmentation contrasts biopharmaceutical, semi-synthetic, and synthetic sources to assess innovation streams and manufacturing complexity. Lastly, Combination Therapy segmentation differentiates multiple drug regimens-such as 5-aminosalicylates plus corticosteroids or immune modifiers plus biologics-from single-agent approaches, emphasizing synergistic protocols and safety profiles.

Key Regional Insights in the Americas, EMEA, and Asia-Pacific

Regional dynamics exert a profound influence on the adoption, pricing, and regulatory pathways for small molecule IBD therapies. In the Americas, the United States leads adoption of novel oral JAK inhibitors, buoyed by robust clinical trial infrastructure, favorable payer frameworks, and high patient willingness to embrace self-administered treatments. Canada’s growing focus on real-world evidence generation further accelerates post-market validation. Within Europe, Middle East & Africa, heterogeneous healthcare systems shape market entry timelines: Western European nations benefit from centralized regulatory channels and value-based assessment models, while emerging economies in Eastern Europe and parts of the Middle East grapple with budget constraints and reliance on generics. Africa remains an emergent segment where improving infrastructure and international partnerships will be crucial to expand patient access. Across Asia-Pacific, rapid urbanization and rising disposable incomes drive demand in major markets such as China, Japan, and South Korea, where local manufacturing partnerships and streamlined regulatory approvals are catalyzing domestic production. Southeast Asia and Australia/New Zealand exhibit distinct reimbursement landscapes, ranging from government-subsidized programs to private insurance schemes. Consequently, each region presents unique opportunities and barriers that industry stakeholders must navigate to optimize market penetration and patient outcomes.

Key Company Insights Driving Innovation and Market Dynamics

Leading pharmaceutical companies are leveraging diverse portfolios, strategic alliances, and targeted investments to secure leadership in the small molecule IBD segment. AbbVie Inc. continues to expand its research into selective kinase inhibitors while forging partnerships to enhance global supply chain resiliency. Bristol Myers Squibb’s acquisition strategies have bolstered its immunomodulator pipeline, particularly in the realm of next-generation JAK inhibitors. Celgene Corporation’s focused development of oral integrin antagonists underscores its commitment to differentiated modalities. Eli Lilly and Company has advanced its selective JAK inhibitor candidates through adaptive trial designs, emphasizing safety and efficacy in refractory IBD populations.

Meanwhile, Galapagos NV’s collaborative ventures with major biopharmaceutical players facilitate accelerated translational research. Gilead Sciences, Inc. leverages its expertise in small molecule development to optimize oral formulations of established therapies. Janssen Pharmaceuticals, Inc. maintains a robust franchise of TNF inhibitors and IL-23 antagonists while exploring combination therapy regimens to address primary non-responders. Novartis International AG’s global footprint and manufacturing scale enable competitive pricing for synthetic small molecules, complemented by regional bestselling therapies. Pfizer Inc. pioneers digitally enabled patient support programs to drive adherence and long-term outcomes. Takeda Pharmaceutical Company Limited strategically aligns its pipeline with biomarker-driven initiatives, integrating precision medicine into its semi-synthetic drug platforms. Collectively, these companies illustrate the competitive intensity, innovation velocity, and collaborative spirit defining the small molecule IBD market.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize a multifaceted approach to capitalize on market opportunities and mitigate emerging challenges: First, invest in precision medicine platforms that integrate genomic and microbiome data to tailor small molecule therapy selection, optimizing efficacy and reducing adverse events. Second, strengthen supply chain resiliency by diversifying API sourcing, implementing real-time monitoring for tariff exposure, and exploring localized manufacturing partnerships to manage cost pressures. Third, forge strategic alliances with digital health providers to deliver telemedicine solutions, remote monitoring tools, and patient engagement applications that enhance adherence and facilitate proactive disease management. Fourth, design innovative pricing and reimbursement models, including outcomes-based contracts and subscription-style programs, to address payer budgetary constraints while ensuring patient access. Fifth, accelerate post-market evidence generation through registries and real-world data studies to satisfy regulatory requirements, inform clinical guidelines, and support differentiated value propositions. Finally, cultivate talent and organizational agility by embedding cross-functional teams that can rapidly respond to shifting regulatory environments, scientific breakthroughs, and evolving patient expectations.

Conclusion

The small molecule drug segment for inflammatory bowel diseases stands at the nexus of scientific innovation, regulatory evolution, and shifting patient expectations. The proliferation of selective kinase inhibitors, enhanced understanding of immunopathology, and integration of digital health tools are collectively redefining therapeutic paradigms. Nevertheless, external pressures such as revised tariff structures, reimbursement constraints, and regional disparities in healthcare infrastructure underscore the complexity of aligning commercial strategies with clinical needs.

By leveraging precise segmentation insights, harnessing real-world evidence, and fostering collaborative ecosystems spanning academia, policymakers, and technology partners, stakeholders can unlock sustainable growth and, more importantly, deliver meaningful improvements in patient outcomes. Continued vigilance in monitoring market dynamics, coupled with bold investments in personalized therapies and supply chain innovation, will be critical to sustaining momentum in an increasingly competitive landscape.

Market Segmentation & Coverage

This research report categorizes the Small Molecules Drugs for Inflammatory Bowel Diseases Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Crohn's Disease
    • Active Disease
    • Remission Maintenance
  • Ulcerative Colitis
    • Mild to Moderate
    • Moderate to Severe
  • 5-Aminosalicylates
    • Oral Administration
    • Rectal Administration
  • Biologics
    • Integrin Antagonists
    • Interleukin Inhibitors
    • TNF Inhibitors
  • Immune Modifiers
    • Immunomodulators
    • Immunosuppressants
  • Janus Kinase Inhibitors
    • Oral JAK Inhibitors
    • Selective JAK Inhibitors
  • Capsules
  • Injections
    • Pre-filled Syringes
    • Vials
  • Suppositories
  • Tablets
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Adult
    • Middle-aged Adults
    • Senior Adults
    • Young Adults
  • Pediatric
  • Clinics
  • Homecare Settings
  • Hospitals
  • Biopharmaceutical
  • Semi-Synthetic
  • Synthetic
  • Multiple Drug Therapy
    • 5-Aminosalicylates + Corticosteroids
    • Immune Modifiers + Biologics
  • Single Drug Therapy

This research report categorizes the Small Molecules Drugs for Inflammatory Bowel Diseases Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Small Molecules Drugs for Inflammatory Bowel Diseases Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Bristol Myers Squibb
  • Celgene Corporation
  • Eli Lilly and Company
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Disease Type
8.1. Introduction
8.2. Crohn's Disease
8.2.1. Active Disease
8.2.2. Remission Maintenance
8.3. Ulcerative Colitis
8.3.1. Mild to Moderate
8.3.2. Moderate to Severe
9. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Drug Class
9.1. Introduction
9.2. 5-Aminosalicylates
9.2.1. Oral Administration
9.2.2. Rectal Administration
9.3. Biologics
9.3.1. Integrin Antagonists
9.3.2. Interleukin Inhibitors
9.3.3. TNF Inhibitors
9.4. Immune Modifiers
9.4.1. Immunomodulators
9.4.2. Immunosuppressants
9.5. Janus Kinase Inhibitors
9.5.1. Oral JAK Inhibitors
9.5.2. Selective JAK Inhibitors
10. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Dosage Form
10.1. Introduction
10.2. Capsules
10.3. Injections
10.3.1. Pre-filled Syringes
10.3.2. Vials
10.4. Suppositories
10.5. Tablets
11. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Patient Demographics
12.1. Introduction
12.2. Adult
12.2.1. Middle-aged Adults
12.2.2. Senior Adults
12.2.3. Young Adults
12.3. Pediatric
13. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by End users
13.1. Introduction
13.2. Clinics
13.3. Homecare Settings
13.4. Hospitals
14. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Drug Origin
14.1. Introduction
14.2. Biopharmaceutical
14.3. Semi-Synthetic
14.4. Synthetic
15. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Combination Therapy
15.1. Introduction
15.2. Multiple Drug Therapy
15.2.1. 5-Aminosalicylates + Corticosteroids
15.2.2. Immune Modifiers + Biologics
15.3. Single Drug Therapy
16. Americas Small Molecules Drugs for Inflammatory Bowel Diseases Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Small Molecules Drugs for Inflammatory Bowel Diseases Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Small Molecules Drugs for Inflammatory Bowel Diseases Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. AbbVie Inc.
19.3.2. Bristol Myers Squibb
19.3.3. Celgene Corporation
19.3.4. Eli Lilly and Company
19.3.5. Galapagos NV
19.3.6. Gilead Sciences, Inc.
19.3.7. Janssen Pharmaceuticals, Inc.
19.3.8. Novartis International AG
19.3.9. Pfizer Inc.
19.3.10. Takeda Pharmaceutical Company Limited
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET MULTI-CURRENCY
FIGURE 2. SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET MULTI-LANGUAGE
FIGURE 3. SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG ORIGIN, 2024 VS 2030 (%)
FIGURE 20. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG ORIGIN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COMBINATION THERAPY, 2024 VS 2030 (%)
FIGURE 22. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COMBINATION THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ACTIVE DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY REMISSION MAINTENANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN'S DISEASE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MILD TO MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MODERATE TO SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY 5-AMINOSALICYLATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY RECTAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY 5-AMINOSALICYLATES, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INTEGRIN ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY IMMUNE MODIFIERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY IMMUNE MODIFIERS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JANUS KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ORAL JAK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SELECTIVE JAK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JANUS KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY VIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MIDDLE-AGED ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SENIOR ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY BIOPHARMACEUTICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SEMI-SYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MULTIPLE DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY 5-AMINOSALICYLATES + CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY IMMUNE MODIFIERS + BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MULTIPLE DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SINGLE DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN'S DISEASE, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY 5-AMINOSALICYLATES, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY IMMUNE MODIFIERS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JANUS KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MULTIPLE DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN'S DISEASE, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY 5-AMINOSALICYLATES, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY IMMUNE MODIFIERS, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JANUS KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MULTIPLE DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN'S DISEASE, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY 5-AMINOSALICYLATES, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY IMMUNE MODIFIERS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JANUS KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MULTIPLE DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 118. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 119. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN'S DISEASE, 2018-2030 (USD MILLION)
TABLE 120. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 121. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY 5-AMINOSALICYLATES, 2018-2030 (USD MILLION)
TABLE 123. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 124. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY IMMUNE MODIFIERS, 2018-2030 (USD MILLION)
TABLE 125. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JANUS KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 126. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 127. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 128. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 130. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 131. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 132. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 133. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 134. CANADA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MULTIPLE DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 135. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 136. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN'S DISEASE, 2018-2030 (USD MILLION)
TABLE 137. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 138. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY 5-AMINOSALICYLATES, 2018-2030 (USD MILLION)
TABLE 140. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 141. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY IMMUNE MODIFIERS, 2018-2030 (USD MILLION)
TABLE 142. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JANUS KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 143. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 144. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 145. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 147. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 148. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 149. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 150. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 151. MEXICO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MULTIPLE DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN'S DISEASE, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY 5-AMINOSALICYLATES, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY IMMUNE MODIFIERS, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JANUS KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MULTIPLE DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN'S DISEASE, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY 5-AMINOSALICYLATES, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY IMMUNE MODIFIERS, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JANUS KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MULTIPLE DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN'S DISEASE, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY 5-AMINOSALICYLATES, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY IMMUNE MODIFIERS, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JANUS KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 196. AUSTRALIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 197. AUSTRALIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 198. AUSTRALIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. AUSTRALIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 200. AUSTRALIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 201. AUSTRALIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 202. AUSTRALIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MULTIPLE DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 205. CHINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 206. CHINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN'S DISEASE, 2018-2030 (USD MILLION)
TABLE 207. CHINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 208. CHINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. CHINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY 5-AMINOSALICYLATES, 2018-2030 (USD MILLION)
TABLE 210. CHINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 211. CHINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY IMMUNE MODIFIERS, 2018-2030 (USD MILLION)
TABLE 212. CHINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JANUS KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 213. CHINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 214. CHINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 215. CHINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. CHINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 217. CHINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 218. CHINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 219. CHINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 220. CHINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 221. CHINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MULTIPLE DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 222. INDIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 223. INDIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN'S DISEASE, 2018-2030 (USD MILLION)
TABLE 224. INDIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 225. INDIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 226. INDIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY 5-AMINOSALICYLATES, 2018-2030 (USD MILLION)
TABLE 227. INDIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 228. INDIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY IMMUNE MODIFIERS, 2018-2030 (USD MILLION)
TABLE 229. INDIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JANUS KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 230. INDIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 231. INDIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 232. INDIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. INDIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 234. INDIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 235. INDIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 236. INDIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 237. INDIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 238. INDIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MULTIPLE DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 239. INDONESIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 240. INDONESIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN'S DISEASE, 2018-2030 (USD MILLION)
TABLE 241. INDONESIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 242. INDONESIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 243. INDONESIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY 5-AMINOSALICYLATES, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY IMMUNE MODIFIERS, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JANUS KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 247. INDONESIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 248. INDONESIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 249. INDONESIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 250. INDONESIA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030

Companies Mentioned

  • AbbVie Inc.
  • Bristol Myers Squibb
  • Celgene Corporation
  • Eli Lilly and Company
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Related Topics

Related Reports

Inflammatory Bowel Disease Treatment Market by Type, Drug Class, Route of Administration, Distribution Channel - Global Forecast 2025-2030 - Product Image

Inflammatory Bowel Disease Treatment Market by Type, Drug Class, Route of Administration, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Ulcerative Colitis - Pipeline Insight, 2025 - Product Image

Ulcerative Colitis - Pipeline Insight, 2025

  • Clinical Trials
  • 240 Pages
  • Global
From
Ulcerative Colitis Market Report 2025 - Product Image

Ulcerative Colitis Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn's Disease, Ulcerative Colitis), By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn's Disease, Ulcerative Colitis), By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 120 Pages
  • Global
From
Inflammatory Bowel Disease (IBD) Therapeutics - Global Strategic Business Report - Product Image

Inflammatory Bowel Disease (IBD) Therapeutics - Global Strategic Business Report

  • Report
  • 146 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.